Sector News

Lilly announces changes in senior management

March 2, 2017
Life sciences

Eli Lilly and Company today announced changes in its executive committee.

Johna Norton will be promoted to senior vice president of global quality April 1, replacing Fionnuala Walsh, who is retiring April 15 after 28 years at Lilly. Norton currently is vice president, Global Quality for API Manufacturing, Product Research and Development.
Bart Peterson, senior vice president of Corporate Affairs and Communications, will leave Lilly March 31 to pursue personal business interests and expand his community volunteer commitments. Peterson, a former two-term mayor of Indianapolis, joined Lilly in 2009. A search currently is under way for his replacement.

“Fionnuala and Bart have been invaluable members of our executive committee as our business has gone through tremendous transformation during the last few years,” said David Ricks, Lilly president and CEO. “Fionnuala has worked diligently to ensure that we have maintained the highest quality standards across our worldwide operations, which is absolutely essential to our business. And, Bart’s leadership and political acumen have been vital to help us meet the significant challenges of an incredibly complex health care environment. His strong passion and vision for global health has been instrumental in making life better for people around the world.”

Ricks said Lilly is very fortunate to have Norton to step into Walsh’s role. “Johna lives Lilly’s values every day, has a strong commitment to our mission, sets the highest standards for her work and has demonstrated leadership in partnering across the business. She has a deep knowledge of our manufacturing and quality systems and has worked effectively with regulators globally.”

Source: Eli Lilly and Company

comments closed

Related News

November 28, 2021

Founder-led biotech is making space for ideas—and diverse leaders—where it didn’t exist before

Life sciences

Decades ago, the founder-led biotech was rare and considered the tougher path to follow. Now there is a trend of founder-led biotechs that have risen in prominence in recent years, going from startup to well known with lightning speed. Scientists-turned C-suite occupants know their technology inside out. They’ve got credibility both at the bench working with their research teams and in the boardrooms selling their future products.

November 28, 2021

Pfizer to become $100B behemoth next year thanks to COVID-19 drug and vaccine: analyst

Life sciences

Pfizer’s revenue could reach $101.3 billion in 2022, with major contributions coming from the company’s BioNTech-partnered COVID vaccine and an antiviral therapeutic that has shown stellar clinical data, SVB Leerink analyst Geoffrey Porges projected in a Monday note to clients.

November 28, 2021

GlaxoSmithKline takes aim at sick pay access inequities with microgrant program and new campaign

Life sciences

In a survey commissioned by GlaxoSmithKline’s consumer health division of 2,000 working people in the U.S., almost 70% admitted to clocking in while sick, often because they couldn’t afford to lose a day’s pay. Black and Latina women were 10% more likely than white women to shun taking sick time for fear of fallout from their boss, according to the company’s 2021 Temperature Check Report.

Send this to a friend